The Daily The New York Times

Warning: This episode contains descriptions of rape, sexual abuse and death.

As an epidemic of fentanyl use continues in America, causing tens of thousands of deaths each year, lawmakers and law enforcement agencies are holding one group increasingly responsible: drug users themselves.

Eli Saslow, a writer for The Times, tells the story of a man whose friendship ended in tragedy and a set of laws that say he is the one to blame.

Guest: Eli Saslow, a writer at large for The New York Times.

Warning: This episode contains descriptions of violence.

The relationship between two democratic allies fell to its lowest point in history this week, after Canada accused India of assassinating a Sikh community leader in British Columbia in June.

Mujib Mashal, The Times’s South Asia bureau chief, explains this stunning accusation — and what India’s reaction to it tells us about the era of its leader, Narendra Modi.

Guest: Mujib Mashal, The New York Times’s bureau chief for South Asia.

New research and polling show that more and more Americans now doubt a previously unquestioned fact of U.S. life — that going to college is worth it.

Paul Tough, a contributing writer for The New York Times Magazine, explains why so many high-school students and their parents are souring on higher education and what it will mean for the country’s future.

Guest: Paul Tough, a contributing writer for The New York Times Magazine who has written several books on inequality in education.

As Ukraine’s counteroffensive grinds on, it’s increasingly turning to a secret drone program that is hitting targets deep inside Russian territory. At least three different Ukrainian-made drones have been used in attacks inside Russia, including on Moscow, according to an analysis by The New York Times.

Christiaan Triebert, a journalist on The Times’s Visual Investigations team, explains the origins of that program. We also speak to Serhiy Prytula, a former Ukrainian television host who is now a key force behind it.

Guest: Christiaan Triebert, a journalist on The New York Times’s Visual Investigations team.

Drugs like Ozempic are revolutionizing the treatment of obesity. The medications, originally used to treat diabetes, keep gaining attention as celebrities and other influencers describe taking them to lose weight quickly. Dani Blum, a reporter for The Times, tells the story behind the drugs and describes some of the ramifications of using them.

Twenty years ago, a glamorous platinum-blond widow arrived at the Paris law office of Claude Dumont Beghi in tears. Someone was trying to take her horses — her “babies” — away, and she needed a lawyer to stop them.

She explained that her late husband had been a breeder of champion thoroughbreds. The couple was a familiar sight at the racetracks in Chantilly and Paris: Daniel Wildenstein, gray-suited with a cane in the stands, and Sylvia Roth Wildenstein, a former model with a cigarette dangling from her lips. They first met in 1964, while she was walking couture shows in Paris and he was languishing in a marriage of convenience to a woman from another wealthy Jewish family of art collectors. Daniel, 16 years Sylvia’s senior, already had two grown sons when they met, and he didn’t want more children. So over the next 40 years they spent together, Sylvia cared for the horses as if they were the children she never had. When Daniel died of cancer in 2001, he left her a small stable.

Then, one morning about a year later, Sylvia’s phone rang. It was her horse trainer calling to say that he had spotted something odd in the local racing paper, Paris Turf: The results of Sylvia’s stable were no longer listed under her name. The French journalist Magali Serre’s 2013 book “Les Wildenstein” recounts the scene in great detail: Sylvia ran to fetch her copy and flipped to the page. Sure enough, the stable of “Madame Wildenstein” had been replaced by “Dayton Limited,” an Irish company owned by her stepsons.